المؤلفون: Jeremy L. Davis, Bradford J. Wood, Elizabeth Gil Ramirez, Gagandeep Brar, Cecilia Monge Bonilla, Freddy E. Escorcia, Melissa Walker, Jennifer Jones, Tim F. Greten, Donna Mabry-Hrones, Austin G. Duffy, Deborah Citrin, David E. Kleiner, Seth M. Steinberg, Billel Gasmi, Jonathan M. Hernandez, Suzanne Fioravanti, Changqing Xie, Bernadette Redd

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research. 26(10)

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Durvalumab, Pilot Projects, Antibodies, Monoclonal, Humanized, Radiosurgery, Gastroenterology, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Tissue Distribution, Adverse effect, Immune Checkpoint Inhibitors, Aged, Aged, 80 and over, business.industry, Antibodies, Monoclonal, Middle Aged, Prognosis, Confidence interval, Immune checkpoint, Blockade, Pancreatic Neoplasms, Survival Rate, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Cohort, Toxicity, Female, business, Tremelimumab, medicine.drug, Carcinoma, Pancreatic Ductal, Follow-Up Studies

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4e6456ae1a28e453383372345b34396
https://pubmed.ncbi.nlm.nih.gov/33397682